Please wait
0001716166
EX-FILING FEES
S-1
POS AM
0001716166
2026-01-02
2026-01-02
0001716166
1
2026-01-02
2026-01-02
0001716166
2
2026-01-02
2026-01-02
0001716166
3
2026-01-02
2026-01-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Exhibit
107
Calculation
of Filing Fee Tables
FORM
S-3
(Form
Type)
Vivos
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
333-278564
Table
3: Combined Prospectuses
N/A
Combined Prospectuses
| Security Type | |
Security Class Title | |
Amount
of
Securities
Previously
Registered
(1) | | |
Maximum
Aggregate
Offering
Price of
Securities
Previously
Registered | | |
Form Type | |
File Number | |
Initial
Effective Date |
| Equity | |
Common Stock issuable upon exercise of November 2023 Warrant (2) | |
| 980,393 | | |
$ | 4,148,043 | | |
S-1 | |
333-275726 | |
December 1, 2023 |
| Equity | |
Common Stock issuable upon exercise of January 2023 Warrant (3) | |
| 266,667 | | |
$ | 1,021,335 | | |
S-1 | |
333-278564 | |
April 26, 2024 |
| Equity | |
Common Stock issuable upon exercise of February 2024 Warrant (4) | |
| 735,296 | | |
$ | 3,713,245 | | |
S-1 | |
333-278564 | |
April 26, 2024 |
(1)
In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional
securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar
transactions.
(2)
Consists of 980,393 shares of Common Stock that are issuable upon exercise of the November 2023 Warrant originally registered for resale
on the Registration Statement on Form S-1 (File No. 333-275726).
(3)
Consists of 266,667 shares of Common Stock that are issuable upon exercise of the January 2023 Warrant originally registered for resale
on the Registration Statement on Form S-1 (File No. 333-278564)(the “April 2024 Registration Statement”).
(4)
Consists of 735,296 shares of Common Stock that are issuable upon exercise of the February 2024 Warrant originally registered for resale
on the April 2024 Registration Statement.